Impact of the 21-gene recurrence score assay in clinical treatment and prognosis analysis for patients with hormone receptor positive early-stage breast cancer
10.3760/cma.j.issn.0253-3766.2018.02.006
- VernacularTitle: 21基因检测复发风险评分在激素受体阳性早期乳腺癌临床治疗和预后评估中的价值
- Author:
Yanna ZHANG
1
;
Yidong ZHOU
;
Feng MAO
;
Jinghong GUAN
;
Yan LIN
;
Xuejing WANG
;
Songjie SHEN
;
Changjun WANG
;
Ru YAO
;
Qiang SUN
Author Information
1. Department of Breast Surgery, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100730, China
- Publication Type:Clinical Trail
- Keywords:
Breast neoplasms;
Prognosis;
21-gene assay;
Recurrence score
- From:
Chinese Journal of Oncology
2018;40(2):110-114
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To explore the association between the 21-gene recurrence score (RS) and clinicopathologic characteristics as well as prognosis in patients with axillary lymph node negative, hormone receptor (HR) positive breast cancer.
Methods:The clinicopathologic data of 439 early breast cancer patients who underwent 21 gene RS testing was retrospectively analyzed. According to the 21 gene RS, the patients were divided into low risk (295 cases), intermediate risk (111 cases) and high-risk (33 cases) group. The relationship between the 21 gene RS and clinicopathological characteristics, treatment, recurrence and metastasis was analyzed. Univariate and multivariate statistical analyses were used to analyze the risk factors for relapse free survival (RFS).
Results:Tumor grade, estrogen receptor (ER), progesterone receptor (PR) and Ki-67 index were significantly different among the 3 risk cohorts (P<0.001 for all). After a median follow-up of 32 months, the recurrence rate in low risk group (3.7%) was significantly lower than that in the intermediate-high risk group (9.0%), the locoregional recurrence (LRR) rate of low, intermediate and high risk group was 2.4%, 6.3% and 9.1%; and the distant metastasis (DM) rate in low risk group was 1.4% and 2.1% in the intermediate-high risk group. Univariate analysis showed RS, ER status and endocrine therapy were prognostic factors for RFS (P<0.05 for all). Multivariate analysis showed that RS was an independent significant predictor for RFS (P=0.04).
Conclusions:The 21-gene RS is related to tumor grade, ER, PR and Ki-67 index. RS is an independent risk factor for RFS in patients with hormone receptor positive early-stage breast cancer.
